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Sir,
Ceftaroline is a new cephalosporin antibiotic with activity against
MRSA. Binding of this drug to the allosteric domain of PBP2a leads
to a conformational change that allows a second molecule of cef-
taroline to bind to the active site, blocking its activity.1 Recent
reports have described MRSA isolates with low-level (.1–8 mg/L)
and high-level (.32 mg/L) resistance to ceftaroline.2 – 5 These
have been isolated in geographically dispersed locations
(Greece, Spain, Switzerland, Thailand and the USA) and have
occurred in numerous genetic backgrounds: ST5 [clonal complex
(CC) 5], ST228 (CC5), ST239 (CC8), ST247 (CC8) and ST764 (CC5).2–5
Low-level resistance has been associated with N146K, E150K and
E239K substitutions in the allosteric binding domain of PBP2a.1 –3
Recent data have shown that the N146K/E150K substitutions medi-
ate resistance by interrupting the allosteric response of ceftaroline
binding, preventing a second molecule of ceftaroline blocking the
active site.6 Higher-level resistance (8 to .32 mg/L) is mediated
by E447K and Y446N/E447K substitutions in the ceftaroline-binding
pocket of the transpeptidase region of PBP2a.2,5 Furthermore, the
E447K substitution has been identified in laboratory-generated,
ceftaroline-resistant isolates, along with other chromosomal muta-
tions likely to be involved in high-level resistance.7
We sought the presence of these mutations in the whole-
genome sequence data of 458 MRSA isolates cultured from
humans (n¼397) or animals (n¼61). Isolates from humans
were predominantly drawn from the east of England between
1985 and 1987 (n¼180) or between 2006 and 2013 (n¼191),
with the remainder drawn from other regions of England and
Scotland between 2010 and 2012.8,9 Animal isolates were
cultured from dogs (41), cats (3), horses (4) or cattle (13) in the
UK.8 We identified three isolates (0.66%) that contained Ta
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substitutions previously reported to mediate ceftaroline resist-
ance (Table 1). Two isolates (ASARM167 and A38) belonging to
ST22 (epidemic MRSA-15) had an E239K substitution in PBP2a.
ASARM167 was isolated from a patient with bacteraemia at
Cambridge University Hospitals NHS Foundation Trust (CUH) in
2008 and A38 was isolated from a canine wound infection in
2006 treated in Wiltshire, south-west England.8 Phylogenetic ana-
lysis of these two isolates based on core genome SNPs placed
them in different clades separated by .120 SNPs (data not
shown), indicating that the E239K mutation arose independently
in these two isolates. The third isolate (ASARM130) had the N146K
substitution in PBP2a, belonged to ST241 (CC8) and was isolated
from a patient with bacteraemia at CUH in 2007. This isolate was
also noted to have an N204K substitution, which has not been
reported previously in isolates with the N146K substitution.2,3
The effect of these PBP2a substitutions on the ceftaroline resist-
ance phenotype was evaluated for these three isolates using the
disc diffusion assay based on EUCAST guidelines10 and the Etest
(bioMe´rieux, Lyon, France) according to the manufacturer’s instruc-
tions. Two isolates were susceptible and one was resistant to cef-
taroline by disc diffusion, but all three isolates were susceptible by
Etest (Table 1). Although isolates with the N146K substitution
have been reported previously to have an MIC of 0.5 mg/L (suscep-
tible), all previously reported isolates with E239K had an MIC of
≥2 mg/L (resistant).2,4 The lack of association between a resistant
phenotype and the N146K substitution indicates that secondary
chromosomal mutations are likely to be involved, as reported previ-
ously.4,7 The three study isolates were cultured before the clinical
introduction of ceftaroline into clinical practice in the USA in 2010
and Europe in 2012, demonstrating that these are natural variants
of PBP2a that occur (albeit at low prevalence) even without pressure
from ceftaroline use. All previously reported isolates with PBP2a sub-
stitutions mediating ceftaroline resistance belonged to CC5 and
CC8, which has led to the suggestion that these two lineages
might be more prone to such mutations. Our findings suggest
that they probably occur in multiple MRSA lineages including the
pandemic CC22 lineage, which is important in many parts of the
world including Australia and the Middle East and is the dominant
MRSA lineage in the UK and much of Europe.
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